ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Feinstein Institutes Bioelectronic Medicine Researchers Target Specific Vagus Nerve Fibers for More Precise, Effective Stimulation

A new study published in the journal Brain Stimulation shows that high electrical frequency stimulation can activate specific nerve fibers in the body

Electrically stimulating the vagus nerve has shown potential to treat inflammatory diseases, including rheumatoid arthritis, lupus and diabetes. Now, a team of bioelectronic medicine scientists at The Feinstein Institutes for Medical Research is one step closer to developing more precise, selective neuromodulation techniques. A new paper published in Brain Stimulation showed that delivering high-frequency electrical stimulation activates specific sensory nerve fibers of the vagus nerve and could be the key to better targeting and treating inflammation and disease.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221104005611/en/

Dr. Stavros Zanos recently led the study, which targets specific fibers in the vagus nerve for more precise electrical stimulation. (Credit: Feinstein Institutes)

Dr. Stavros Zanos recently led the study, which targets specific fibers in the vagus nerve for more precise electrical stimulation. (Credit: Feinstein Institutes)

The research study, led by Stavros Zanos, MD, PhD, associate professor at the Feinstein Institutes Institute of Bioelectronic Medicine, measured how vagus nerve stimulation (VNS) using kHz stimulation – an electrical stimulus that is commonly used to block nerve conduction at over 1,000 pulses per second affects the activity of different types of vagal fibers. Previous VNS therapies would stimulate the whole nerve bluntly, without targeting specific fibers, which could cause adverse effects and less effective therapy. For example, in past clinical trials, side effects from the vocal cords and from coughing reflex prevented clinicians from delivering the full dose of VNS, and thus limited the therapeutic effect.

“The vagus nerve is one of the most important nerves in our body, which helps us maintain our daily functions like breathing and our heart rate. Being able to target certain nerve fibers is a huge step for precision stimulation,” said Dr. Zanos, senior author of the paper. “This selective stimulation in the vagus nerve has not been achieved until now and our results will help researchers find new therapies to treat diseases.”

The vagus nerve is made up of 100,000 individual fibers. It acts as an information pipeline in the body, stretching from the brain to the organs helping to maintain bodily functions and immune response. If the vagus nerve is overactive or underactive inflammatory diseases can arise. The field of bioelectronic medicine combines molecular medicine, neuroscience and biomedical engineering to develop innovative therapies using computer chips and devices instead of drugs to treat those diseases.

By stimulating the vagus nerve with high frequency, Dr. Zanos and his team were able to consistently activate the small unmyelinated nerve fibers while at the same time bypassing the activation of larger fibers in the nerve – which are usually the first to be activated by VNS and are responsible for most unwanted side-effects. The study was done in two animal models (mice and rats) and if validated in humans, could be leveraged in novel bioelectronic therapies.

“Dr. Zanos discovered how to selectively activate nerve fibers traveling in the vagus nerve by manipulating the electric frequency,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. “This work significantly advances the field of bioelectronic medicine and opens new pathways to explore experimental therapeutics.”

The Feinstein Institutes for Medical Research was recently awarded $6.7 million from the National Institutes of Health (NIH). The funding will help Dr. Zanos and his lab create a detailed map of the anatomy of the human vagus nerve. The funding is part of the NIH Common Fund’s Stimulating Peripheral Activity to Relieve Conditions (SPARC) program.

About the Feinstein Institutes

The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.56
+0.02 (0.01%)
AAPL  274.61
+0.50 (0.18%)
AMD  209.17
+1.59 (0.77%)
BAC  54.81
-0.52 (-0.94%)
GOOG  307.73
-1.59 (-0.51%)
META  657.15
+9.64 (1.49%)
MSFT  476.39
+1.57 (0.33%)
NVDA  177.72
+1.43 (0.81%)
ORCL  188.65
+3.73 (2.02%)
TSLA  489.88
+14.57 (3.07%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.